Location Directory

Clinical trials in Portland, Oregon

This page shows live ClinicalTrials.gov search results for Portland, Oregon, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9377

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Diabetic Macular Edema (DME)
Interventions: Remigromig, Ranibizumab; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 107
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more

Conditions: Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Interventions: Zanzalintinib, Everolimus; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 158
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more

Conditions: Obesity or Overweight
Interventions: Lenbelintide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 41
States / cities: Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 38 more

Conditions: Mitral Valve Regurgitation
Interventions: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2036
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 57 more

Conditions: Asthma
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 65
States / cities: Bakersfield, California • Huntington Beach, California • La Mesa, California + 61 more

Conditions: Pregnancy Related
Interventions: Wearable Activity Tracker; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation
Interventions: Not listed
Lead sponsor: CoMind Technologies Limited; Industry
Eligibility: 18 Years and older
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Phoenix, Arizona • Sacramento, California • Wilmington, Delaware + 14 more

Conditions: Melanoma, Cutaneous Malignant, Mucosal Melanoma
Interventions: IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel; Biological · Drug
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more

Conditions: Mesial Temporal Lobe Epilepsy
Interventions: NRTX-1001, Sham Comparator; Biological · Procedure
Lead sponsor: Neurona Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2043
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 180 Days to 22 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 108
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 85 more

Conditions: Muscular Atrophy, Spinal
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Months to 36 Months
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 6 more

Clinical trials in Portland, Oregon

Filter and sort this location

Live official records

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Assessing the Use of Wearable Activity Trackers in a Pregnancy Cohort

CoMind Early Feasibility Study

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)